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Introduction
Treatment with levodopa or dopaminergic agonists has been associated with the development of diffuse hair loss, predominantly in females. In most of the reported cases this hair loss was reversible after cessation of medication, although in some, it persisted 1,2 . More recently, telogen effluvium has also been reported in association with the dopamine agonist pramipexole in a woman with Parkinsons's disease 3 leading to speculation that hair loss may be overlooked in such patients 4 .
However, it is unknown whether dopamine and other dopamine receptor agonists directly impact human hair growth, rather than modulating other hormones that regulate hair growth, and whether human scalp hair follicles (HFs) express dopamine receptors (DRs). Dopamine acts via G-protein coupled DRs, of which five types have been identified. DR are classified on the basis of their effect on adenylate cyclase, with D1R and D5R being stimulatory and D2R, D3R and D4R inhibitory 5 . Peripheral dopamine production is thought to arise from neurons, the adrenal medulla and neuroendocrine cells 6 Interestingly, dopamine agonists can exert anti-proliferative effects on cultured human dermal fibroblasts 7 , and dopamine may regulate angiogenesis during cutaneous wound healing 8 . Human skin possesses the essential enzymes not only for dopamine metabolism, but also for dopamine synthesis, namely, dihydroxyphenylalanine (DOPA) decarboxylase and dopamine β hydroxylase 9 ; human HF
Materials and Methods
Microdissected anagen VI HFs were obtained from redundant scalp skin, as a by-product of cosmetic surgery, with ethical approval (University of Lübeck, Reference 06-109), adherence to the Helsinki Declaration principles, and written informed consent. Microdissected HFs were cultured in supplemented serum-free culture medium protocol for 7 days as described 11 with the addition of dopamine (protected from light; Sigma-Aldrich, Taufkirchen) 10nM -1000nM or culture medium only. These concentrations were selected on the basis of previous studies, with the addition of a higher dopamine concentration (1000nM) 5 . Hair shaft elongation was measured as percentage elongation from baseline, and hair cycle stage and hair cycle score determined morphometrically as described 12 . HFs were embedded in Cryomatrix (Thermo Shandon, Cheshire, UK), snap frozen in liquid nitrogen, cryosectioned (6μm) and Ki/TUNEL 13 , Masson-Fontana, tyrosinase activity in situ and Gp100 immunoreactivity (IR) 14 were performed as previously reported. Statistical analysis was performed as detailed in Fig.1 . "Real time" PCR for was performed as described in (Supplementary Fig. 3b ).
Results
Dopamine 1000nM increased the percentage of HFs in the catagen phase of the hair cycle, which was consistent with a significant increase in the hair cycle score (p=0.03; Fig. 1a, b) .
Hair cycle score, calculated as previously described, accurately indicates hair cycle stage 15 .
This was independently confirmed by assessing HF pigmentation, since catagen development switches off melanin production. Masson-Fontana quantitative histomorphometry showed a significant reduction in melanin staining (p=0.04) (Fig. 1c- Since these findings showed that dopamine can directly inhibit the growth of isolated human HF in serum-free organ culture, this suggested that human scalp HFs also express DRs.
Indeed, DR1 transcription was demonstrated in both HFs and skin. That was indeed the case was confirmed by "real time" PCR ( Supplementary Fig. 3b ).
Discussion
This study provides the first direct evidence that dopamine treatment negatively affects human hair growth, namely that it promotes HF regression (catagen) in female anagen VI HFs in organ culture, i.e. in the absence of neural or vascular cues. This is entirely consistent with the in vivo case reports of hair loss in patients being treated with dopaminergic agonists 1, 3, 4, 16, 17 . Moreover, this study demonstrates that dopamine reduces HF matrix keratinocyte proliferation.
Whilst the precise mechanism(s) by which dopamine induced premature catagen development in female human anagen HFs remains to be elucidated, the intrafollicular presence of DR transcripts suggests a DR-mediated mechanism ( Supplementary Fig 3b) . It has already been shown that murine skin expresses DRs 18 , with DR2 localised to the basal layer of the epidermis. DR2 agonist treatment resulted in reduced epidermal hyperplasia in response to barrier disruption. In cultured human epidermal keratinocytes, treatment with the dopaminergic agonist bromocriptine also reduced proliferation 18 . Our finding that dopamine is a catagen promoter and can inhibit human hair matrix keratinocyte proliferation in situ is in line with these studies.
Given the evidence that prolactin treatment can stimulate the growth of female frontotemporal
HFs in vitro 19 , we speculate that dopamine could have reduced intra-follicular prolactin Dopamine is a novel, direct inducer of catagen in human scalp hair follicles.
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